Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 5/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | GCK | P35557 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | BCL2 | P10415 | 2/20 | 0.33 |
| ▸ | BCL2L2 | Q92843 | 2/20 | 0.33 |
| ▸ | FABP3 | P05413 | 1/20 | 0.33 |
| ▸ | FABP4 | P15090 | 1/20 | 0.33 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8512988 | 0.90 | MCL1 (0.41) | MCL1FFAR1KMT2ABCL2BCL2L2 | |
| SCHEMBL8514582 | 0.84 | MCL1 (0.41) | MCL1FFAR1KMT2AGCKBCL2 | |
| SCHEMBL955452 | 0.83 | GCK (0.43) | SMN1; SMN2GCK | |
| SCHEMBL8515253 | 0.82 | KMT2A (0.51) | MCL1KMT2ABCL2BCL2L2 | |
| SCHEMBL935524 | 0.82 | HIF1A (0.40) | MCL1KMT2ASMN1; SMN2TDP1BCL2 | |
| SCHEMBL8513005 | 0.82 | BCL2L1 (0.42) | MCL1KMT2ATDP1 | |
| SCHEMBL8515249 | 0.81 | LPAR1 (0.41) | MCL1KMT2AGCKBCL2BCL2L2 | |
| SCHEMBL8515246 | 0.81 | MCL1 (0.41) | MCL1KMT2ABCL2BCL2L2PTGS2 | |
| SCHEMBL8516017 | 0.81 | PPARG (0.40) | MCL1MRGPRX4FFAR1KMT2ABCL2 | |
| SCHEMBL8516044 | 0.81 | HIF1A (0.42) | MCL1FFAR1KMT2ABCL2BCL2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2456767-B1 | PYRIDONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | claimed |
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-05-23 | — | — | US | claimed |
| EP-2456767-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2012-05-30 | — | — | EP | claimed |
| CN-102471322-A | Pyridone glucokinase activators | HOFFMANN LA ROCHE | 2012-05-23 | — | — | CN | claimed |
| EP-2456767-B1 | PYRIDONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2456767-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2012-05-30 | — | — | EP | disclosed |
| CN-102471322-A | Pyridone glucokinase activators | HOFFMANN LA ROCHE | 2012-05-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | GCK, PDXK, G6PD | MCL1 4634/4885MRGPRX4 3794/4885FFAR1 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.